BME:FAE

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Faes Farma, S.A., a pharmaceutical company, researches, develops, produces, and commercializes pharmaceutical products and raw materials. More Details


Snowflake Analysis

Solid track record with excellent balance sheet.


Similar Companies

Share Price & News

How has Faes Farma's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: FAE has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

3.0%

FAE

2.8%

ES Pharmaceuticals

0.5%

ES Market


1 Year Return

-22.7%

FAE

9.8%

ES Pharmaceuticals

-20.2%

ES Market

Return vs Industry: FAE underperformed the Spanish Pharmaceuticals industry which returned 9.8% over the past year.

Return vs Market: FAE underperformed the Spanish Market which returned -20.2% over the past year.


Shareholder returns

FAEIndustryMarket
7 Day3.0%2.8%0.5%
30 Day9.5%4.1%0.4%
90 Day-6.6%-1.8%-3.8%
1 Year-20.6%-22.7%13.3%9.8%-17.6%-20.2%
3 Year40.7%28.2%31.1%16.0%-20.1%-27.4%
5 Year81.3%56.7%37.7%13.9%-7.3%-21.8%

Price Volatility Vs. Market

How volatile is Faes Farma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Faes Farma undervalued compared to its fair value and its price relative to the market?

10.3%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: FAE (€3.64) is trading below our estimate of fair value (€4.05)

Significantly Below Fair Value: FAE is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: FAE is good value based on its PE Ratio (13.8x) compared to the XE Pharmaceuticals industry average (21.5x).

PE vs Market: FAE is good value based on its PE Ratio (13.8x) compared to the Spanish market (18.7x).


Price to Earnings Growth Ratio

PEG Ratio: FAE is poor value based on its PEG Ratio (2.8x)


Price to Book Ratio

PB vs Industry: FAE is good value based on its PB Ratio (2.3x) compared to the XE Pharmaceuticals industry average (3.4x).


Next Steps

Future Growth

How is Faes Farma forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

4.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: FAE's forecast earnings growth (4.9% per year) is above the savings rate (1.3%).

Earnings vs Market: FAE's earnings (4.9% per year) are forecast to grow slower than the Spanish market (31.7% per year).

High Growth Earnings: FAE's earnings are forecast to grow, but not significantly.

Revenue vs Market: FAE's revenue (1.7% per year) is forecast to grow slower than the Spanish market (6.2% per year).

High Growth Revenue: FAE's revenue (1.7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: FAE's Return on Equity is forecast to be low in 3 years time (13.2%).


Next Steps

Past Performance

How has Faes Farma performed over the past 5 years?

19.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: FAE has high quality earnings.

Growing Profit Margin: FAE's current net profit margins (17.9%) are higher than last year (16.2%).


Past Earnings Growth Analysis

Earnings Trend: FAE's earnings have grown by 19% per year over the past 5 years.

Accelerating Growth: FAE's earnings growth over the past year (23.5%) exceeds its 5-year average (19% per year).

Earnings vs Industry: FAE earnings growth over the past year (23.5%) exceeded the Pharmaceuticals industry 13.2%.


Return on Equity

High ROE: FAE's Return on Equity (16.4%) is considered low.


Next Steps

Financial Health

How is Faes Farma's financial position?


Financial Position Analysis

Short Term Liabilities: FAE's short term assets (€273.8M) exceed its short term liabilities (€82.4M).

Long Term Liabilities: FAE's short term assets (€273.8M) exceed its long term liabilities (€7.1M).


Debt to Equity History and Analysis

Debt Level: FAE's debt to equity ratio (3%) is considered satisfactory.

Reducing Debt: FAE's debt to equity ratio has increased from 1.3% to 3% over the past 5 years.

Debt Coverage: FAE's debt is well covered by operating cash flow (572.2%).

Interest Coverage: FAE's interest payments on its debt are well covered by EBIT (1446.1x coverage).


Balance Sheet


Next Steps

Dividend

What is Faes Farma current dividend yield, its reliability and sustainability?

0.72%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: FAE's dividend (0.72%) isn’t notable compared to the bottom 25% of dividend payers in the Spanish market (2.29%).

High Dividend: FAE's dividend (0.72%) is low compared to the top 25% of dividend payers in the Spanish market (6.42%).


Stability and Growth of Payments

Stable Dividend: FAE is not paying a notable dividend for the Spanish market, therefore no need to check if payments are stable.

Growing Dividend: FAE is not paying a notable dividend for the Spanish market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: FAE is not paying a notable dividend for the Spanish market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of FAE's dividend in 3 years as they are not forecast to pay a notable one for the Spanish market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

7.3yrs

Average board tenure


CEO

Faes Farma has no CEO, or we have no data on them.


Board Members

NamePositionTenureCompensationOwnership
Mariano Ucar Angulo
Chairman of the Board of Directors7.25yrs€919.00k0.41%
€ 4.2m
Iñigo Zavala Ortiz de la Torre
Director26.25yrs€63.00k0.77%
€ 7.9m
Carmen Basagoiti Pastor
Director8.25yrs€57.00k0.0029%
€ 29.5k
Francisco Javier de Usaola García
Director7.25yrs€57.00k0.16%
€ 1.6m
Carlos de Alcocer Torra
Independent Director7.25yrs€64.00k0.32%
€ 3.3m
Belén Amatriain Corbi
Independent Directorno datano data0.00013%
€ 1.3k
Eugenia Zugaza Salazar
Independent Director1.67yrsno datano data

7.3yrs

Average Tenure

Experienced Board: FAE's board of directors are considered experienced (7.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.5%.


Top Shareholders

Company Information

Faes Farma, S.A.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Faes Farma, S.A.
  • Ticker: FAE
  • Exchange: BME
  • Founded: 1933
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €1.021b
  • Shares outstanding: 280.91m
  • Website: https://faesfarma.com

Number of Employees


Location

  • Faes Farma, S.A.
  • Parque empresarial "Cristalia" Calle Vía de los Poblados 3
  • Edificio 2, 2º Izquierda (Hortaleza)
  • Madrid
  • Madrid
  • 28033
  • Spain

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
FAEBME (Bolsas y Mercados Espanoles)YesOrdinary SharesESEUROct 1989
FFEADB (Deutsche Boerse AG)YesOrdinary SharesDEEUROct 1989
0K9HLSE (London Stock Exchange)YesOrdinary SharesGBEUROct 1989
FAEEBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBEUROct 1989

Biography

Faes Farma, S.A., a pharmaceutical company, researches, develops, produces, and commercializes pharmaceutical products and raw materials. The company's product portfolio includes prescription drugs, generi ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/20 03:51
End of Day Share Price2020/09/18 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.